Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Goldman Sachs Ups Braveheart Bio to Strong-Buy

Guavy AI Editorial Team
Instruments
GS
Share

Braveheart Bio (NASDAQ:BRVE) has received an upgrade to 'Strong-Buy' from The Goldman Sachs Group, according to a research note issued on Monday.

The upgrade is one of several recent ratings changes for the biopharmaceutical company. TD Cowen, Stifel Nicolaus, Cantor Fitzgerald, and Jefferies Financial Group have all initiated coverage with 'buy' or 'overweight' ratings.

Braveheart Bio's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive hypertrophic cardiomyopathy and non-obstructive hypertrophic cardiomyopathy.

More on Stocks

Stocks just now

Holy Crap Launches on Amazon U.S., Restart Life Sciences Expands Product Line

Stocks 1m ago

FTC Lawsuit Slams Amazon Stock, But Analysts Remain Bullish on Future Growth

Stocks 1m ago

Google Jumps 50% Price Hike for TV Streamer 4K Amid Component Cost Increases

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy